Washington D.C.

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions

• HIV11 trials
• Lung cancer3 trials
• Colorectal cancer2 trials
• Head and neck cancer1 trial
• Liver and biliary tract cancer1 trial
• Lupus (SLE)1 trial
• Melanoma1 trial
• Multiple myeloma1 trial
• Systemic sclerosis (scleroderma)1 trial

Phase

• Phase 310 trials
• Phase 12 trials
• Phase 22 trials
• Phase 2/32 trials
• Phase 42 trials
• Phase 1/21 trial

Status

• Active, not recruiting9 trials
• Recruiting5 trials
• Completed4 trials
• Withdrawn1 trial

Lead sponsor

• ViiV Healthcare11 trials
• GlaxoSmithKline6 trials
• Tesaro, Inc.2 trials

Running trials

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· ViiV Healthcare· Source

  Contact: Theo Hodge (principal investigator)

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: Kimberley Doucette (principal investigator)

• Active, not recruiting

  A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

  NCT06694805· Phase 3· ViiV Healthcare· Source

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Christopher Gallagher (principal investigator)

• Recruiting

  A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  NCT05878717· Phase 2/3· GlaxoSmithKline· Source

  Contact: Virginia Steen (principal investigator)

• Active, not recruiting

  A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

  NCT05996471· Phase 2· ViiV Healthcare· Source

• Recruiting

  Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

  NCT05674656· Phase 1/2· ViiV Healthcare· Source

  Contact: Natella Rakhmanina (principal investigator)

• Active, not recruiting

  Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

  NCT04655976· Phase 2/3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

  NCT03299049· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

  NCT02951052· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

  NCT02938520· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

  NCT02817633· Phase 1· Tesaro, Inc.· Source

• Active, not recruiting

  Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

  NCT02715284· Phase 1· Tesaro, Inc.· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV2 recruiting
• Head and neck cancer1 recruiting
• Multiple myeloma1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

  NCT05911360· Phase 3· ViiV Healthcare· Source

• Completed

  A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

  NCT05514509· Phase 4· ViiV Healthcare· Source

• Completed

  A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

  NCT05374525· Phase 4· ViiV Healthcare· Source

• Completed

  Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

  NCT01649765· Phase 2· GlaxoSmithKline· Source